A hormonal contraceptive for men: How close are we?

Progress in Brain Research

Volumn 181, Issue C, 2010, Pages 273-288

  Huhtaniemi, Ilpo ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Gonadotropins; Male contraception; Progestins; Sex steroids; Spermatogenesis; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CONTRACEPTIVE AGENT; CYTOCHROME P450 3A4; DESOGESTREL; ETONOGESTREL; FOLLITROPIN; GESTAGEN; GONADORELIN; GONADOTROPIN; INHIBIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; ORAL CONTRACEPTIVE AGENT;

ACNE; ANDROGEN SYNTHESIS; ARTICLE; AZOOSPERMIA; BONE DENSITY; CANCER RISK; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG INDUSTRY; FINANCE; GENETIC DIFFERENCE; HEMATOCRIT; HORMONAL CONTRACEPTION; HORMONE RELEASE; HUMAN; LIBIDO; LONG TERM CARE; MOOD CHANGE; MUSCLE STRENGTH; NONHUMAN; OLIGOSPERMIA; POLITICS; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SPERMATOGENESIS; TESTIS SIZE; WEIGHT GAIN; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CONTRACEPTION; DRUG EFFECT; FEMALE; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; METABOLISM; METHODOLOGY; PHYSIOLOGY; REVIEW;

ANDROGENS; AZOOSPERMIA; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MOLECULAR STRUCTURE; PITUITARY-ADRENAL SYSTEM; PROGESTINS; SPERMATOGENESIS;

EID: 77955499768     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)81015-1     Document Type: Article

References (70)

1. Abel, M. H., Wootton, A. N., Wilkins, V., Huhtaniemi, I., Knight, P. G., & Charlton, H. M. (2000). The effect of a null mutation in the follicle-stimulating hormone receptor gene on mouse reproduction. Endocrinology, 141, 1795-1803.
2. Amory, J. K., Page, S. T., Anawalt, B. D., Coviello, A. D., Matsumoto, A. M., & Bremner, W. J. (2007). Elevated end-of-treatment serum INSL3 is associated with failure to completely suppress spermatogenesis in men receiving male hormonal contraception. Journal of Andrology, 28, 548-554.
3. Anderson, R. A. & Baird, D. T. (2002). Male contraception. Endocrine Reviews, 23, 735-762.
4. Anderson, R. A., Wallace, A. M., &Wu, F. C. (1996). Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. Journal of Clinical Endocrinology and Metabolism, 81, 902-908.
5. Bagatell, C. J., Matsumoto, A. M., Christensen, R. B., Rivier, J. E., & Bremner, W. J. (1993). Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. Journal of Clinical Endocrinology and Metabolism, 77, 427-432.
6. Behre, H. M., Nashan, D., Hubert, W., & Nieschlag, E. (1992). Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. Journal of Clinical Endocrinology and Metabolism, 74, 84-90.
7. Bhasin, S. & Jasuja, R. (2009). Selective androgen receptor modulators as function promoting therapies. Current Opinion in Clinical Nutrition and Metabolic Care, 12, 232-240.
8. Bhasin, S., Woodhouse, L., & Storer, T. W. (2001). Proof of the effect of testosterone on skeletal muscle. The Journal of Endocrinology, 170, 27-38.
9. Blithe, D. (2008). Male contraception: What is on the horizon? Contraception, 78, S23-S27.
10. Brady, B. M., Amory, J. K., Perheentupa, A., Zitzmann, M., Hay, C. J., Apter, D., et al. (2006). A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Human Reproduction, 21, 285-294.
11. Cooper, C. S., MacIndoe, J. H., Perry, P. J., Yates, W. R., & Williams, R. D. (1996). The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. The Journal of Urology, 156, 438-441, discussion 441-432.
12. Crawford, E. D. & Hou, A. H. (2009). The role of LHRH antagonists in the treatment of prostate cancer. Oncology (Williston Park, New York), 23, 626-630.
13. Doehn, C., Sommerauer, M., & Jocham, D. (2009). Degarelix for prostate cancer. Expert Opinion on Investigational Drugs, 18, 851-860.
14. Eckardstein, S. V., Schmidt, A., Kamischke, A., Simoni, M., Gromoll, J., & Nieschlag, E. (2002). CAG repeat length in the androgen receptor gene and gonadotropin suppression influence the effectiveness of hormonal male contraception. Clinical Endocrinology, 57, 647-655.
15. El-Hefnawy, T., Manna, P. R., Luconi, M., Baldi, E., Slotte, J. P., & Huhtaniemi, I. (2000). Progesterone action in a murine Leydig tumor cell line (mLTC-1), possibly through a nonclassical receptor type. Endocrinology, 141, 247-255.
16. Fu, H., Darroch, J. E., Haas, T., & Ranjit, N. (1999). Contraceptive failure rates: New estimates from the 1995 national survey of family growth. Family Planning Perspectives, 31, 56-63.
17. Glasier, A. F., Anakwe, R., Everington, D., Martin, C. W., van der Spuy, Z., Cheng, L., et al. (2000). Would women trust their partners to use a male pill? Human Reproduction, 15, 646-649.
18. Grimes, D. A., Lopez, L. M., Gallo, M. F., Halpern, V., Nanda, K., & Schulz, K. F. (2007). Steroid hormones for contraception in men. Cochrane Database of Systematic Reviews (Online), Apr 18; (2): CD004316.
19. Gu, Y., Liang, X., Wu, W., Liu, M., Song, S., Cheng, L., et al. (2009). Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. Journal of Clinical Endocrinology and Metabolism, 94, 1910-1915.
20. Gu, Y.Q., Wang, X.H., Peng, L., Cheng, L.F., Huang. M.K., Huang, Z.J., & Zhang, G.Y. (2003). A munticenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. Journal of Clinical Endocrinology and Metabolism, 88, 562-568.
21. Handelsman, D. J., Farley, T. M., Peregoudov, A., & Waites, G. M. (1995). Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertility and Sterility, 63, 125-133.
22. Handelsman, D. J., Wishart, S., & Conway, A. J. (2000). Oestradiol enhances testosterone-induced suppression of human spermatogenesis. Human Reproduction, 15, 672-679.
23. Heckel, N. (1939). Production of oligospermia in a man by the use of testosterone propionate. Proceedings of the Society for Experimental Biology and Medicine, 40, 658-659.
24. Heinemann, K., Saad, F., Wiesemes, M., White, S., & Heinemann, L. (2005). Attitudes toward male fertility control: Results of a multinational survey on four continents. Human Reproduction, 20, 549-556.
25. Herbst, K. L., Anawalt, B. D., Amory, J. K., Matsumoto, A. M., & Bremner, W. J. (2003). The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but attenuates a decrease in fat mass induced by testosterone alone. Journal of Clinical Endocrinology and Metabolism, 88, 1167-1173.
26. Herbst, K. L., Coviello, A. D., Page, S., Amory, J. K., Anawalt, B. D., & Bremner, W. J. (2004). A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. Journal of Clinical Endocrinology and Metabolism, 89, 5959-5965.
27. Huhtaniemi, I., Nikula, H., & Rannikko, S. (1985). Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: Acute and long term effects on endocrine functions of testis tissue. Journal of Clinical Endocrinology and Metabolism, 61, 698-704.
28. Huhtaniemi, I., Nikula, H., & Rannikko, S. (1987). Pituitarytesticular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels. Journal of Andrology, 8, 355-362.
29. Jones, A., Chen, J., Hwang, D. J., Miller, D. D., & Dalton, J. T. (2009). Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro,4-chlorophenoxy)-2- hydroxy-2-methyl-propanamide: A selective androgen receptor modulator for hormonal male contraception. Endocrinology, 150, 385-395.
30. Kinniburgh, D., Anderson, R. A., & Baird, D. T. (2001). Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. Journal of Andrology, 22, 88-95.
31. Kopf, G. S. (2008). Approaches to the identification of new nonhormonal targets for male contraception. Contraception, 78, S18-S22.
32. Kornmann, B., Nieschlag, E., Zitzmann, M., Gromoll, J., Simoni, M., & von Eckardstein, S. (2009). Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men. Journal of Andrology, 30, 602-613.
33. Kost, K., Singh, S., Vaughan, B., Trussell, J., & Bankole, A. (2008). Estimates of contraceptive failure from the 2002 national survey of family growth. Contraception, 77, 10-21.
34. Kumar, T. R.,Wang, Y., Lu, N., &Matzuk,M.M. (1997). Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nature Genetics, 15, 201-204.
35. LaMorte, A., Kumar, N., Bardin, C. W., & Sundaram, K. (1994). Aromatization of 7 alpha-methyl-19-nortestosterone by human placental microsomes in vitro. The Journal of Steroid Biochemistry and Molecular Biology, 48, 297-304.
36. Liu, P. Y., Swerdloff, R. S., Anawalt, B. D., Anderson, R. A., Bremner, W. J., Elliesen, J., et al. (2008). Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: An integrated analysis. Journal of Clinical Endocrinology and Metabolism, 93, 1774-1783.
37. Matthiesson, K. L. & McLachlan, R. I. (2006). Male hormonal contraception: Concept proven, product in sight? Human Reproduction Update, 12, 463-482.
38. Matthiesson, K. L., Stanton, P. G., O'Donnell, L., Meachem, S. J., Amory, J. K., Berger, R., et al. (2005). Effects of testosterone and levonorgestrel combined with a 5alphareductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men. Journal of Clinical Endocrinology and Metabolism, 90, 5647-5655.
39. McCullagh, E. & McGurl, F. (1939). Further observations on the clinical use of testosterone propionate. The Journal of Urology, 42, 1265-1267.
40. McLachlan, R. I., Robertson, D. M., Pruysers, E., Ugoni, A., Matsumoto, A. M., Anawalt, B. D., et al. (2004). Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. Journal of Clinical Endocrinology and Metabolism, 89, 142-149.
41. Meriggiola,M. C., Bremner, W. J., Paulsen, C. A., Valdiserri, A., Incorvaia, L.,Motta, R., et al. (1996). A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. Journal of Clinical Endocrinology and Metabolism, 81, 3018-3023.
42. Meriggiola, M. C., Costantino, A., Cerpolini, S., Bremner, W. J., Huebler, D., Morselli-Labate, A. M., et al. (2003). Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. Journal of Clinical Endocrinology and Metabolism, 88, 5818-5826.
43. Meriggiola, M. C., Costantino, A., Saad, F., D'Emidio, L., Morselli Labate, A.M., Bertaccini, A., et al. (2005). Norethisterone enanthate plus testosterone undecanoate for male contraception: Effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. Journal of Clinical Endocrinology and Metabolism, 90, 2005-2014.
44. Mommers, E., Kersemaekers, W. M., Elliesen, J., Kepers, M., Apter, D., Behre, H. M., et al. (2008). Male hormonal contraception: A double-blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 93, 2572-2580.
45. Naz, R. K., Engle, A., & None, R. (2009). Gene knockouts that affect male fertility: Novel targets for contraception. Frontiers in Bioscience, 14, 3994-4007.
46. Nieschlag, E. (2009). Male hormonal contraception: Love's labour's lost? Journal of Clinical Endocrinology and Metabolism, 94, 1890-1892.
47. Page, S. T., Amory, J. K., Anawalt, B. D., Irwig, M. S., Brockenbrough, A. T., Matsumoto, A. M., et al. (2006). Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. Journal of Clinical Endocrinology and Metabolism, 91, 4374-4380.
48. Page, S. T., Amory, J. K., & Bremner, W. J. (2008). Advances in male contraception. Endocrine Reviews, 29, 465-493.
49. Page, S. T., Kalhorn, T. F., Bremner, W. J., Anawalt, B. D., Matsumoto, A. M., & Amory, J. K. (2007). Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. Journal of Andrology, 28, 734-741.
50. Pavlou, S. N., Brewer, K., Farley, M. G., Lindner, J., Bastias, M. C., Rogers, B. J., et al. (1991). Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. Journal of Clinical Endocrinology and Metabolism, 73, 1360-1369.
51. Plant, T. M. & Marshall, G. R. (2001). The functional significance of FSH in spermatogenesis and the control of its secretion in male primates. Endocrine Reviews, 22, 764-786.
52. Rajalakshmi, M. & Ramakrishnan, P. R. (1989). Pharmacokinetics and pharmacodynamics of a new long-acting androgen ester: Maintenance of physiological androgen levels for 4 months after a single injection. Contraception, 40, 399-412.
53. Schultz, N., Hamra, F. K., & Garbers, D. L. (2003). A multitude of genes expressed solely in meiotic or postmeiotic spermatogenic cells offers a myriad of contraceptive targets. Proceedings of the National Academy of Sciences of the United States of America, 100, 12201-12206.
54. Singh, J., O'Neill, C., & Handelsman, D. J. (1995). Induction of spermatogenesis by androgens in gonadotropin-deficient (hpg) mice. Endocrinology, 136, 5311-5321.
55. Sipila, P., Jalkanen, J., Huhtaniemi, I. T., & Poutanen, M. (2009). Novel epididymal proteins as targets for the development of post-testicular male contraception. Reproduction, 137, 379-389.
56. Tapanainen, J. S., Aittomaki, K., Min, J., Vaskivuo, T., & Huhtaniemi, I. T. (1997). Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility. Nature Genetics, 15, 205-206.
57. Trussell, J. (2004). Contraceptive failure in the United States. Contraception, 70, 89-96.
58. Turner, L., Conway, A. J., Jimenez, M., Liu, P. Y., Forbes, E., McLachlan, R. I., et al. (2003). Contraceptive efficacy of a depot progestin and androgen combination in men. Journal of Clinical Endocrinology and Metabolism, 88, 4659-4667.
59. von Eckardstein, S., Noe, G., Brache, V., Nieschlag, E., Croxatto, H., Alvarez, F., et al. (2003). A clinical trial of 7 alphamethyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. Journal of Clinical Endocrinology and Metabolism, 88, 5232-5239.
60. Wallace, E. M., Gow, S. M., & Wu, F. C. (1993). Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. Journal of Clinical Endocrinology and Metabolism, 77, 290-293.
61. Walton, M. J., Kumar, N., Baird, D. T., Ludlow, H., & Anderson, R. A. (2007). 7Alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. Journal of Andrology, 28, 679-688.
62. Wenk, M. & Nieschlag, E. (2006). Male contraception: A realistic option? The European Journal of Contraception and Reproductive Health Care, 11, 69-80.
63. World Health Organization (WHO) (1990). Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet, 336, 955-959.
64. World Health Organization (WHO) (1996). Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertility and Sterility, 65, 821-829.
65. Yu, B. & Handelsman, D. J. (2001). Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia. Journal of Clinical Endocrinology and Metabolism, 86, 4406-4411.
66. Zhang, F. P., Pakarainen, T., Poutanen, M., Toppari, J., & Huhtaniemi, I. (2003). The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis. Proceedings of the National Academy of Sciences of the United States of America, 100, 13692-13697.
67. Zhang, L., Shah, I. H., Liu, Y., Vogelsong, K. M., & Zhang, L. (2006). The acceptability of an injectable, once-a-month male contraceptive in China. Contraception, 73, 548-553.
68. Zirkin, B. R., Santulli, R., Awoniyi, C. A., & Ewing, L. L. (1989). Maintenance of advanced spermatogenic cells in the adult rat testis: Quantitative relationship to testosterone concentration within the testis. Endocrinology, 124, 3043-3049.
69. Zitzmann, M., Erren, M., Kamischke, A., Simoni, M., & Nieschlag, E. (2005). Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. Journal of Clinical Endocrinology and Metabolism, 90, 6603-6608.
70. Zitzmann, M. & Nieschlag, E. (2007). Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 92, 3844-3853.